

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) September 25, 2000

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in charter)

Virginia	001-13467	56-1641133
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

601 Biotech Drive, Richmond, Virginia	23235
-----	-----
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (804) 648-3820

N/A

(Former name or former address, if changed since last report)

Item 5. Other Events.

On September 27, 2000, the Registrant issued a press release announcing the completion of a \$2.6 million private placement of common stock and warrants to purchase common stock to a single accredited investor. Such press release is included as an exhibit to this Current Report on Form 8-K.

Item 7. Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Exhibits.

99.1 Press Release, dated September 27, 2000, announcing the completion of a \$2.6 million private placement of common stock and warrants to purchase common stock to a single investor.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

COMMONWEALTH BIOTECHNOLOGIES, INC.

By: /s/ Richard J. Freer, Ph.D.

Richard J. Freer, Ph.D.
Chairman

September 28, 2000

3

EXHIBIT INDEX

Number - - - - -	Description of Exhibit -----
99.1	Press Release, dated September 27, 2000

4

